MALMÖ, SE / ACCESS Newswire / April 8, 2025 / Ascelia Pharma (STO:ACE) - Ascelia Pharma AB (publ) (ticker:ACE), a biotech focused on improving the life of people living with rare cancer conditions, ...

A new editorial was published in , Volume 16, on April 4, 2025, titled "Deep learning-based uncertainty quantification for quality assurance in hepatobiliary imaging-based techniques." ...

A new editorial was published in Oncotarget, Volume 16, on April 4, 2025, titled “Deep learning-based uncertainty ...

A Cleveland Clinic-led clinical trial of tolebrutinib, an investigational oral Bruton's tyrosine kinase inhibitor, a group of drugs originally developed to treat lymphomas and related blood disorders, ...

Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis. Results from the HERCULES phase 3 study showed delay in disability ...

Drug-induced hepatitis is an example of acute liver inflammation, as it will resolve once the offending drug is stopped. The same is seen with hepatitis A, which will spontaneously clear once the ...

Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis Results from the HERCULES phase 3 study showed delay in disability progression in people ...

Model predictions were compared with clinical diagnoses obtained from paired abdominal ultrasound or MRI studies. A total of 1,596,640 echocardiogram videos from 66,922 studies and 24,276 patients at ...

MRI measures of efficacy included the number of new/newly enlarged T2 lesions, gadolinium-enhanced (Gd+ ... 7.8% in the IFN-switch group), mostly due to an increase in liver enzymes by >5-fold of the ...

Cleveland: A Cleveland Clinic-led clinical trial of tolebrutinib, an investigational oral Bruton's tyrosine kinase inhibitor ...

Discover a recent study that analysed CT imaging findings from 48 pathologically confirmed cases of hepatic CE.